Analysts diverge on Willis Towers Watson: MS cuts to $330, Truist raises to $400
Morgan Stanley cut WTW price target to $330 from $345 and kept an Equal Weight rating, citing persistent property and casualty pricing pressure and AI-related headwinds. Truist raised its target to $400 from $380 with a Buy rating after Q4 earnings beat, reaffirming mid-single-digit organic growth guidance across segments.
1. Morgan Stanley Lowers Price Target
Morgan Stanley reduced its price target on Willis Towers Watson to $330 from $345 while maintaining an Equal Weight rating. The firm pointed to ongoing property and casualty insurance pricing pressure and AI-related headwinds weighing on industry profitability.
2. Truist Raises Target and Maintains Buy Rating
Truist increased its price target to $400 from $380 and reiterated a Buy rating following WTW’s stronger-than-expected fourth-quarter performance. The upgrade reflects confidence in the company’s ability to sustain outperformance through differentiated underwriting capabilities.
3. Reaffirmed Organic Growth Guidance
Management reaffirmed expectations for mid-to-high single-digit organic growth in Risk & Broking and mid-single-digit growth in Health, Wealth & Career, supporting overall sustainable mid-single-digit growth. This steady outlook underpins investor confidence in long-term revenue streams.
4. Industry Pressures and Long-Term Appeal
While sector pricing remains soft, insurers with superior risk selection and durable margins like WTW are positioned to outperform. Continued investment in AI-driven analytics and underwriting tools may enhance competitive differentiation over the long term.